
- /
- Supported exchanges
- / US
- / INDP.NASDAQ
Indaptus Therapeutics Inc (INDP NASDAQ) stock market data APIs
Indaptus Therapeutics Inc Financial Data Overview
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Indaptus Therapeutics Inc data using free add-ons & libraries
Get Indaptus Therapeutics Inc Fundamental Data
Indaptus Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -15 994 887
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: -0.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Indaptus Therapeutics Inc News

Indaptus Therapeutics raises $5.7 million through convertible notes
NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ:INDP), whose stock has declined over 80% in the past year and currently trades at $10.53, announced Tuesday it has raised an additional $3.4 million thro...


Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral in...

Indaptus Therapeutics announces sale of $2.3M of convertible notes, warrants
* Indaptus Therapeutics (NASDAQ:INDP [https://seekingalpha.com/symbol/INDP]) has announced the sale of ~$2.3M in aggregate principal amount of convertible promissory notes and accompanying warrants....

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral in...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.